DANA-FARBER CANCER INSTITUTE, INC. patent applications published on March 21st, 2024

Summary of the patent applications from DANA-FARBER CANCER INSTITUTE, INC. on March 21st, 2024

The DANA-FARBER CANCER INSTITUTE, INC. has recently filed patents related to novel biomarkers and methods for sensitizing cancer cells to T cell-mediated killing, compounds targeting the Hedgehog signaling pathway for treating cell proliferative disorders, and methods for identifying tumor-specific T-cell clonotypes for adoptive cell transfer in cancer treatment.

Summary in bullet points:

• Patents focus on novel biomarkers and methods to sensitize cancer cells to T cell-mediated killing, compounds targeting the Hedgehog signaling pathway, and methods for identifying tumor-specific T-cell clonotypes for adoptive cell transfer.
• Applications include cancer immunotherapy, personalized medicine for cancer treatment, and drug development for cancer and other cell proliferative disorders.

Notable applications:

• Cancer immunotherapy
• Precision medicine for cancer treatment
• Drug development for cancer and other cell proliferative disorders

Patent applications for DANA-FARBER CANCER INSTITUTE, INC. on March 21st, 2024

COMPOUNDS FOR TAU PROTEIN DEGRADATION (18200950)

Main Inventor

Nathanael S. Gray

GENERATION OF ANTI-TUMOR T CELLS (18224865)

Main Inventor

Catherine J. Wu

COMPOUNDS AND METHODS FOR TREATING CANCER (18503556)

Main Inventor

James Bradner

METHODS FOR SENSITIZING CANCER CELLS TO T CELL-MEDIATED KILLING BY MODULATING MOLECULAR PATHWAYS (18234229)

Main Inventor

Deng Pan

C-RAF Mutants that Confer Resistance to RAF Inhibitors (18464360)

Main Inventor

Caroline Emery

MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors (18461820)

Main Inventor

Levi A. Garraway